Sanofi gets rated buy today ... I think could contribute to continued top-line performance is a diversified portfolio of ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

with the goal of generating high-quality materials that comply with best practices. Data privacy is also embedded throughout ...

The revamp is the first major action by recently-appointed chief executive Olivier Brandicourt, who took the top job ... bundles Sanofi's generic medicines and older products still in patent ...

The aim is to prepare for the onset of biosimilar competition in the 2030s to Sanofi’s current immunology blockbuster Dupixent (dupilumab), which is predicted to top $14 billion in sales this ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...